Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects
- PMID: 23212430
Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects
Abstract
Kratom (Mitragyna speciosa) is a plant indigenous to Thailand and Southeast Asia. Kratom leaves produce complex stimulant and opioid-like analgesic effects. In Asia, kratom has been used to stave off fatigue and to manage pain, diarrhea, cough, and opioid withdrawal. Recently, kratom has become widely available in the United States and Europe by means of smoke shops and the Internet. Analyses of the medical literature and select Internet sites indicate that individuals in the United States are increasingly using kratom for the self-management of pain and opioid withdrawal. Kratom contains pharmacologically active constituents, most notably mitragynine and 7-hydroxymitragynine. Kratom is illegal in many countries. Although it is still legal in the United States, the US Drug Enforcement Administration has placed kratom on its "Drugs and Chemicals of Concern" list. Physicians should be aware of the availability, user habits, and health effects of kratom. Further research on the therapeutic uses, toxic effects, and abuse potential of kratom and its constituent compounds are needed.
Similar articles
-
Update on the Pharmacology and Legal Status of Kratom.J Am Osteopath Assoc. 2016 Dec 1;116(12):802-809. doi: 10.7556/jaoa.2016.156. J Am Osteopath Assoc. 2016. PMID: 27893147
-
The pharmacology and toxicology of kratom: from traditional herb to drug of abuse.Int J Legal Med. 2016 Jan;130(1):127-38. doi: 10.1007/s00414-015-1279-y. Epub 2015 Oct 28. Int J Legal Med. 2016. PMID: 26511390 Review.
-
Kratom policy: The challenge of balancing therapeutic potential with public safety.Int J Drug Policy. 2019 Aug;70:70-77. doi: 10.1016/j.drugpo.2019.05.003. Epub 2019 May 16. Int J Drug Policy. 2019. PMID: 31103778 Free PMC article.
-
The neuropharmacology of kratom, a novel psychoactive natural product.Prog Neuropsychopharmacol Biol Psychiatry. 2025 Jan 10;136:111215. doi: 10.1016/j.pnpbp.2024.111215. Epub 2024 Dec 9. Prog Neuropsychopharmacol Biol Psychiatry. 2025. PMID: 39662722 Review.
-
Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.J Ethnopharmacol. 2020 Mar 1;249:112462. doi: 10.1016/j.jep.2019.112462. Epub 2019 Dec 7. J Ethnopharmacol. 2020. PMID: 31816368
Cited by
-
Effects of Mitragynine and a Crude Alkaloid Extract Derived from Mitragyna speciosa Korth. on Permethrin Elimination in Rats.Pharmaceutics. 2015 Mar 27;7(2):10-26. doi: 10.3390/pharmaceutics7020010. Pharmaceutics. 2015. PMID: 25825913 Free PMC article.
-
Breakthrough Seizure Associated With Kratom Use in Patients With Epilepsy.Neurol Clin Pract. 2021 Feb;11(1):78-84. doi: 10.1212/CPJ.0000000000000846. Neurol Clin Pract. 2021. PMID: 33968476 Free PMC article. Review.
-
New directions in the treatment of opioid withdrawal.Lancet. 2020 Jun 20;395(10241):1938-1948. doi: 10.1016/S0140-6736(20)30852-7. Lancet. 2020. PMID: 32563380 Free PMC article. Review.
-
Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain.Life Sci. 2023 Sep 1;328:121878. doi: 10.1016/j.lfs.2023.121878. Epub 2023 Jun 29. Life Sci. 2023. PMID: 37392779 Free PMC article.
-
Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder.Molecules. 2024 Feb 23;29(5):984. doi: 10.3390/molecules29050984. Molecules. 2024. PMID: 38474495 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical